Clinical Trial Update: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Eli Lilly's LY4050784 is being studied in a Phase 1 trial for advanced or metastatic solid tumors and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Smarca4-deficient Tumor
• Solid Tumor

Drugs mentioned

• LY4050784 (LY4050784)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Solid Tumor, Advanced Solid Tumor | Phase 1 | Status: RECRUITING